JPMorgan Downgrades Cerevel Therapeutics (CERE) to Neutral

JPMorgan analyst Jessica Fye downgraded Cerevel Therapeutics (NASDAQ: CERE) from Overweight to Neutral with a price target of $29.00 (from $40.00).

For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.

Shares of Cerevel Therapeutics closed at $24.32 yesterday.

You May Also Be Interested In

• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
• Diversified Royalty Corp (DIV:CN) (BEVFF) PT Lowered to Cdn$4.75 at Desjardins